TAM June/July 2026 CME Posttest
Continuing Medical Education Posttest
The following Topics in Antiviral Medicine™ issue offers continuing medical education (CME) credit:
June/July 2026, Volume 34, Issue 3
Overview
- CME Credit Available: 4.5 AMA PRA Category 1 Credits™
- Release Date: July 16, 2026
- Expiration Date: July 16, 2027
To complete the activity, read each article and successfully complete the posttest and evaluation form, which will help us evaluate this activity and plan future activities. Your responses will not affect your CME credit.
Learning Objectives
On completion of this activity, which contains 9 articles on important new data presented at the 2026 Conference on Retroviruses and Opportunistic Infections, the learner will be better able to:
- Summarize available evidence on islatravir susceptibility and incorporate this information into clinical decision-making, particularly in the presence of previously selected or transmitted resistance mutations
- Describe an integrated approach combining behavioral, pharmacologic, and procedural strategies to manage weight gain and obesity in people with HIV
- Describe the latest findings on clinical pharmacology presented at the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs
- List foundational strategies to mitigate frailty and sarcopenia in people with HIV
- Describe a conceptual framework for understanding neurodivergence in the context of HIV, summarize available epidemiologic and outcomes data, and incorporate practical strategies for delivering neurodiversity-affirming, accessible care
Assessment of Needs
The IAS–USA offers this state-of-the-art activity as part of a nationwide CME effort for physicians in the evolving challenges of managing HIV and other viral infections.
Intended Audience
This enduring material is designed for physicians who are actively involved in the medical care of people with HIV and other viral infections. This activity is also relevant for other practitioners, including nurse practitioners, nurses, physician assistants, pharmacists, and others.
CME Information
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this enduring material for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is offered from July 16, 2026, to July 16, 2026. Participants who successfully complete the activity posttest and submit the evaluation and registration forms are eligible to receive CME credit. Physicians (MDs, DOs, and international equivalents) may receive CME credit for completing this activity. Other health care practitioners will receive a certificate of participation.
Disclosure of Financial Interests
It is the policy of the IAS–USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities.
In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.
The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”
IAS–USA has identified and mitigated ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below.
Contributors
Dr Calvez reported serving as an advisor or consultant to and receiving research grant support from Merck Sharp & Dohme, Inc, ViiV Healthcare, and Gilead Sciences, Inc. (Updated February 2, 2026)
Dr Ceccherini-Silberstein reported serving as a consultant to Gilead Sciences, Inc, and Merck Sharp & Dohme, Inc, and receiving research grant support from ViiV Healthcare and Gilead Sciences, Inc. (Updated January 29, 2026)
Dr Charpentier reported serving as an advisor or consultant for ViiV Healthcare, Gilead Sciences, Inc, and MSD Pty, LTD. (Updated February 2, 2026)
Dr Chaudhry reported serving as a consultant for Novo Nordisk. (Updated June 9, 2026)
Dr Eaton reported no relevant financial relationships with ineligible companies. (Updated June 8, 2026)
Dr Erlandson reported serving as a consultant/providing advisory board support to ViiV Healthcare, Gilead Sciences, Inc, and Merck & Co, Inc, and receiving study support in the form of noncash provision of medicines, equipment, or administrative support from Theratechnologies, Inc. (Updated June 8, 2026)
Dr Günthard reported serving as a consultant to Merck & Co, Inc, serving on a data monitoring committee for Merck & Co, Inc, and receiving research grant support from ViiV Healthcare. (Updated June 9, 2026)
Dr Iriarte reported no relevant financial relationships with ineligible companies. (Updated June 8, 2026)
Dr Kashlan reported serving as an advisor for Lina Health Ltd. (Updated June 9, 2026)
Dr Marra reported serving as a consultant or advisor for ViiV Healthcare, Gilead Sciences, Inc, and Pfizer, Inc; grants/grants pending to her institution from ViiV Healthcare, Gilead Sciences, Inc, Pfizer, Inc, and Merck Sharp & Dohme, Inc. (Updated March 4, 2026)
Professor Marzolini reported grants/grants pending to her institution from Gilead Sciences, Inc. (Updated June 8, 2026)
Dr Paredes reported receiving research grant support from ViiV Healthcare, Gilead Sciences, Inc, and Merck Sharp & Dohme, Inc, and serving as a consultant for Gilead Sciences, Inc, Pfizer, Inc, Merck Sharp & Dohme, Inc, and ViiV Healthcare. (Updated February 2, 2026)
Dr Relyea Ashley reported no relevant financial relationships with ineligible companies. (Updated June 9, 2026)
Dr Richman reported no relevant financial relationships with ineligible companies. (Updated May 15, 2026)
Dr Scarsi reported grants/grants pending to her institution from ViiV Healthcare. (Updated May 19, 2026)
Dr Shafer reported no relevant financial relationships with ineligible companies. (Updated June 19, 2026)
Dr Stuart reported no relevant financial relationships with ineligible companies. (Updated June 10, 2026)
Dr Tseng reported serving as a consultant or advisor for Gilead Sciences, Inc, Merck & Co, Inc, Pfizer, Inc, and ViiV Healthcare, and grants/grants pending to her institution from Gilead Sciences, Inc, Merck & Co, Inc, and ViiV Healthcare. (Updated June 9, 2026)
Dr Wensing reported advisor or consulting fees to her institution from Merck Sharp & Dohme, Inc, Roche Laboratories, Gilead Sciences, Inc, and ViiV Healthcare; grants to her institution from Gilead Sciences, Inc; and noncash provision of medicines, equipment, or administrative support to her institution from ARK. (Updated June 8, 2026)
Planners/Reviewers
Planner/Reviewer 1 reported no relevant financial relationships with ineligible companies. (Updated May 15, 2026)
Reviewer 2 reported no relevant financial relationships with ineligible companies. (Updated June 8, 2026)
Planner/Reviewer 3 reported no relevant financial relationships with ineligible companies. (Updated June 19, 2026)
Topics in Antiviral Medicine Editorial Board
Dr Richman reported consulting or advisor fees from Generate Biomedicines and Gilead Sciences, Inc. (Updated May 15, 2026)
Dr Benson reported grants/grants pending to her institution from BioMerieux. (Updated May 15, 2026)
Dr Hirsch reported no relevant financial affiliations with ineligible companies. (Updated June 8, 2026)
Grant Support
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Platinum Supporters
Gilead Sciences, Inc.
Merck & Co, Inc.
ViiV Healthcare
Additional Supporter
Hologic, Inc
Contact Information
If you have any questions about this activity, please contact the IAS–USA:
Email: journal@iasusa.org
Mail: 131 Steuart St, Ste 500, San Francisco, CA 94105
Phone: (415) 544-9400
By clicking the link below, I acknowledge that I have read these instructions and understand them.
You must log in to take the activity.
You must be logged in to access this course.